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Editorial
Glimmer of Hope in the Fight to
Reduce Human Immunodeficiency Virus
Transmission in Pregnancy
Women and children presently comprise the group of human immunodeficiency
virus (HIV) individuals with the highest rate of newly identified HIV infection.
Virtually all newly diagnosed cases of HIV among children occur by vertical
transmission of the virus from mother to infant. This area of HIV research has
yielded the most promising results in reducing the risk of HIV transmission.
Recently, the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials
Group (ACTG) halted enrollment midway through ACTG Study 076 due to the
overwhelming significance of zidovudine treatment in reducing the rate of vertical
transmission (8.3% in the treatment group vs. 25.5% in the placebo group).
This trial was restricted to women with CD4 lymphocyte counts >200 cells/mm3
who had not previously received zidovudine. Other clinical trials aimed at reduc-
ing vertical transmission are currently underway in women with lower CD4 counts
or symptomatic HIV disease.
The report in this issue by Robinson and Fleischer, "Prenatal Human Immun-
odeficienc Virus Testing and Patient Management by Obstetricians in a High
Seroprevalence Community," highlights a crucial challenge facing the providers of
women’s health care today. The challenge is to identify and counsel all I--IIV-
infected women who might benefit from zidovudine and various other treatments
being developed to reduce vertical transmission. The study by Robinson and
Fleischer indicates that, even in a high-seroprevalence community, many obstetri-
cians do not routinely offer I-IIV testing to women without identifiable risk factors.
About 40% of the obstetricians responding did not offer HIV testing to all new
obstetric patients. Furthermore, as many as 15% of obstetricians responded that
they do not routinely even inquire about potential risk factors. Although many
HIV-infected women have no identifiable risk factors, their partners may have
significant risk factors of which these women are unaware. This fact further
emphasizes the need for universal screening during pregnancy.
Obstetricians have the opportunity to positively impact the lives of many I-IIV-
infected women. The first step is to actively offer screening to women. Every
woman deserves the opportunity to be screened for a condition that may signifi-
cantly alter her life and that of her unborn baby, especially as modalities to alter the
outcome are becoming available. The goal is not to coerce women into unwanted
testing but to provide the information and potential benefits that will facilitate
informed choices. Our responsibility goes further than just offering testing and
counseling. Once identified, an I-IIV-positive woman must be provided quality,
comprehensive, nonjudgmental care in a supportive environment if pregnancy and
I-IIV outcomes are to be optimized. If the practitioner feels unqualified to provide
quality care, then appropriate consultation and referrals may be necessary. Whether
providing care directly or through consultations or referral, we as obstetricians
have a responsibility to the women we serve to provide optimal care regardless of
their I--IIV status. Neither can we justify in ourselves nor accept in our colleagues
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judgmental attitudes, refusal to provide services, or other forms of discriminatory
behavior that amount to patient abandonment. We must never lose sight of the fact
that the enemy is HIV disease, not its victims. Ultimately, we all will suffer from
the toll and consequences of I--IIV infection.
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